Corvus Pharmaceuticals Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Corvus Pharmaceuticals stock.
View analyst ratings for Corvus Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Corvus Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Corvus Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Corvus Pharmaceuticals saw a decline in short interest in the month of August. As of August 13th, there was short interest totaling 975,800 shares, a decline of 22.6% from the July 29th total of 1,260,000 shares. Based on an average trading volume of 220,500 shares, the days-to-cover ratio is presently 4.4 days. Approximately 3.5% of the shares of the company are sold short.
View Corvus Pharmaceuticals' Short Interest.

Corvus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Corvus Pharmaceuticals.

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released its quarterly earnings results on Sunday, August, 1st. The company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.32) by $0.04.
View Corvus Pharmaceuticals' earnings history.

Corvus Pharmaceuticals' stock was trading at $2.71 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CRVS shares have increased by 127.7% and is now trading at $6.17.
View which stocks have been most impacted by COVID-19.

3 equities research analysts have issued 12-month price objectives for Corvus Pharmaceuticals' shares. Their forecasts range from $3.50 to $6.00. On average, they expect Corvus Pharmaceuticals' share price to reach $4.83 in the next year. This suggests that the stock has a possible downside of 21.7%.
View analysts' price targets for Corvus Pharmaceuticals or view top-rated stocks among Wall Street analysts.

4 employees have rated Corvus Pharmaceuticals CEO Richard A. Miller, MD on Glassdoor.com. Richard A. Miller, MD has an approval rating of 100% among Corvus Pharmaceuticals' employees. This puts Richard A. Miller, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Corvus Pharmaceuticals include FibroGen (FGEN), Aclaris Therapeutics (ACRS), Applied Molecular Transport (AMTI), Phathom Pharmaceuticals (PHAT), CannTrust (CNTTF), IDEAYA Biosciences (IDYA), GH Research (GHRS), Nkarta (NKTX), Omeros (OMER), ORIC Pharmaceuticals (ORIC), Prometheus Biosciences (RXDX), BELLUS Health (BLUSF), Rani Therapeutics (RANI), Kinnate Biopharma (KNTE) and Vanda Pharmaceuticals (VNDA).
View all of CRVS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Corvus Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Vaxart (VXRT), Zosano Pharma (ZSAN), SCYNEXIS (SCYX), Miragen Therapeutics (MGEN), Aldeyra Therapeutics (ALDX) and Bionano Genomics (BNGO).

(CRVS) raised $75 million in an initial public offering (IPO) on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Credit Suisse and Cowen and Company served as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.

Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."

Corvus Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BVF Inc. IL (8.67%), Vanguard Group Inc. (2.61%), CHI Advisors LLC (1.70%), Renaissance Technologies LLC (1.55%), Dimensional Fund Advisors LP (0.93%) and Telemetry Investments L.L.C. (0.62%). Company insiders that own Corvus Pharmaceuticals stock include Holdings A/S Novo, Orbimed Advisors Llc and Richard A Md Miller.
View institutional ownership trends for Corvus Pharmaceuticals.

CRVS stock was sold by a variety of institutional investors in the last quarter, including Laurion Capital Management LP, Citadel Advisors LLC, Algert Global LLC, Dimensional Fund Advisors LP, Renaissance Technologies LLC, and Goldman Sachs Group Inc..
View insider buying and selling activity for Corvus Pharmaceuticals or view top insider-selling stocks.

CRVS stock was bought by a variety of institutional investors in the last quarter, including BVF Inc. IL, Vanguard Group Inc., Geode Capital Management LLC, CHI Advisors LLC, Millennium Management LLC, State Street Corp, Northern Trust Corp, and Telemetry Investments L.L.C.. Company insiders that have bought Corvus Pharmaceuticals stock in the last two years include Orbimed Advisors Llc, and Richard A Md Miller.
View insider buying and selling activity for Corvus Pharmaceuticals or or view top insider-buying stocks.

Shares of CRVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CRVS stock can currently be purchased for approximately $6.17.

Corvus Pharmaceuticals has a market capitalization of $261.74 million. The company earns $-5,990,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis.

Corvus Pharmaceuticals employs 42 workers across the globe.

The official website for Corvus Pharmaceuticals is www.corvuspharma.com.

Corvus Pharmaceuticals is headquartered at 863 Mitten Road Suite102, BURLINGAME CA, 94010.

Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The company can be reached via phone at (650) 900-4520 or via email at [email protected].